Palmer J A, Kaiser B A, Polinsky M S, Dunn S P, Braas C, Waltz R, Baluarte H J
St. Christopher's Hospital for Children, Department of Nursing, Philadelphia, PA 19134-1095.
Pediatr Nephrol. 1994 Dec;8(6):715-8. doi: 10.1007/BF00869099.
As a foreign body, the peritoneal dialysis (PD) catheter represents a potential source of infection, particularly for immunosuppressed renal transplant patients. A retrospective study was therefore undertaken to compare the risks and benefits of our policy of removing PD catheters at 3 months following renal transplant, which was established to allow for early re-initiation of dialysis. Between 1984 and 1990, 43 renal transplants were performed in 35 children who had been receiving maintenance PD. During the 1st month post transplantation, the PD catheter was used in 25 patients (58%) because of acute rejection or primary allograft non-function. Thirty-one patients were eventually discharged with functioning allografts and a PD catheter in place. Of them, 43% developed a catheter-related infection within the next 2 months, a period during which PD was not performed. Potential contributing factors included a history of catheter-related infection prior to transplantation, use of high-dose methylprednisolone to treat acute rejection, and the type of maintenance immunosuppression prescribed; conversely, the use of prophylactic antibiotics appeared to decrease this risk. This study established the potential need for the catheter during the first few weeks, but because of the infection risk of 43% by 3 months post transplantation, our protocol was revised to include catheter removal at the time of hospital discharge. From 1990 until the end of 1992, an additional 19 PD recipients underwent transplantation. In this group, catheters were used during the 1st month in 6 children (32%). Fifteen patients were discharged with a functioning allograft and only 1 patient returned to PD at 12 months post transplant. It is concluded that PD catheters represent an additional source of infection following transplantation and should be removed at the time of hospital discharge, after which the likelihood of use is low.
作为一种异物,腹膜透析(PD)导管是潜在的感染源,对于免疫抑制的肾移植患者尤其如此。因此,我们进行了一项回顾性研究,以比较我们在肾移植后3个月移除PD导管这一策略的风险和益处,该策略旨在允许早期重新开始透析。1984年至1990年期间,对35名接受维持性PD治疗的儿童进行了43例肾移植手术。移植后的第1个月,25例患者(58%)因急性排斥反应或原发性移植物无功能而使用了PD导管。最终,31例患者的移植肾功能良好且PD导管在位出院。其中,43%的患者在接下来的2个月内发生了与导管相关的感染,在此期间未进行PD治疗。潜在的促成因素包括移植前有导管相关感染史、使用大剂量甲泼尼龙治疗急性排斥反应以及所规定的维持性免疫抑制类型;相反,预防性使用抗生素似乎可降低这种风险。这项研究确定了在最初几周内对导管的潜在需求,但由于移植后至3个月时感染风险达43%,我们的方案进行了修订,改为在出院时移除导管。从1990年到1992年底,又有19例PD接受者接受了移植手术。在这组患者中,6名儿童(32%)在第1个月使用了导管。15例患者移植肾功能良好出院,只有1例患者在移植后12个月恢复了PD治疗。结论是,PD导管是移植后额外的感染源,应在出院时移除,之后再次使用的可能性较低。